Adjuvant therapy for melanoma: How should we respond to high-dose interferon?
de Takats
P G
PG
Oncology Centre, Addenbrooke's NHS Trust, Cambridge, UK.
Williams
M V
MV
Hawkins
R
R
D000328:Adult; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008545:Melanoma / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins; D015996:Survival Rate
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins